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ESSENTIALS 
  MMP-13 has the potential to influence platelet function and thrombus formation 
directly  We sought to elucidate whether MMP-13 is able to bind to specific platelet receptors   MMP-13 is able to bind to platelet alphaIIbbeta3 (αIIbβ3) and glycoprotein (GP)VI   These interactions are sufficient to inhibit platelet aggregation and thrombus formation  
 
 
 
 
 
 
 
 
 
 
 
  
 BACKGROUND.  Acute thrombotic syndromes lead to atherosclerotic plaque rupture with 
subsequent thrombus formation, myocardial infarction and stroke.  Following rupture, flowing 
blood is exposed to plaque components, including collagen, which triggers platelet activation and 
aggregation.  However, plaque rupture releases other components into the surrounding vessel 
which have the potential to influence platelet function and thrombus formation.  OBJECTIVES.  
Here we sought to elucidate whether matrix metalloproteinase-13 (MMP-13), a collagenolytic 
metalloproteinase up–regulated in atherothrombotic and inflammatory conditions, affects 
platelet aggregation and thrombus formation.  RESULTS.  We demonstrate that MMP-13 is able 
to bind to platelet receptors alphaIIbbeta3 (αIIbβ3) and platelet glycoprotein (GP)VI.  The 
interactions between MMP-13, GPVI and αIIbβ3 are sufficient to significantly inhibit washed 
platelet aggregation and decrease thrombus formation on fibrillar collagen.  CONCLUSIONS.  
Our data demonstrate a role for MMP-13 in the inhibition of both platelet aggregation and 
thrombus formation in whole flowing blood, and may provide new avenues of research into the 
mechanisms underlying the subtle role of MMP-13 in atherothrombotic pathologies. 
 
Platelet-extracellular matrix and platelet–platelet adhesions are central to the formation of 
thrombi.  MMP-13 is up-regulated in inflammation, and is elevated in the atherosclerotic 
plaque, contributing to its vulnerability [1].  It is also implicated in the progression and 
remodelling of cerebral tissue in stroke [2].  Plaque rupture releases MMP-13 into the local 
environment where it has direct access to plasma proteins, blood cells and platelets.  Following 
injury to the blood vessel wall, specific platelet receptors mediate platelet–collagen and 
platelet–platelet interactions.  GPIbα binds to immobilised von Willebrand factor (VWF) in the 
vessel wall, initiating platelet capture [3], and glycoprotein (GP)VI binds directly to collagen 
and activates platelets.  Integrin α2β1 stabilises the early stages of the plateletcollagen 
interaction, and integrin αIIbβ3 supports platelet-platelet interactions mediated by fibrinogen 
and VWF [4-7].   
MMP-2 and -9 have previously been shown to bind to platelet receptors and/or to modulate 
platelet function [8-13].  Here, we hypothesised that MMP-13 may also interact directly with 
platelet receptors GPVI, integrin α2β1, or the platelet adhesive integrin αIIbβ3 to modulate 
platelet adhesion, aggregation and thrombus formation.  Our work identifies potential roles for 
MMP-13 in modulating the recruitment or activation of platelets in thrombotic pathologies. 
  
METHODS 
MMP-13 expression, purification and activation 
ProMMP-13 and its MMP-13 catalytic (CAT, 249-451) domain were expressed, purified, 
activated and dialysed as previously described [14-16].  The structurally homologous but 
catalytically inactive ProMMP-13(E204A) was a kind gift from Dr.  R.  Visse (Kennedy 
Institute of Rheumatology Division, Imperial College London, London, UK).  GST-
Hemopexin (HPX) domain (264-471) was expressed in E.  coli using the pGEX-2T expression 
vector, the forward primer TCCGCGTGGATCCCTCTATGGTCCAGGAGATGAA and the 
reverse primer GCAA-ATTCCATTTTGTGGTGTTGAAGAATTCAT, which contain BamHI 
and EcoRI restriction sites respectively, as previously described [16].   
 
Washed platelet preparation and platelet adhesion assays 
Plates were coated with 10 µg/ml MMP-13 variants in Tris buffered saline (TBS) for 1 h at 24 
°C.  Plates were then blocked with 5 % BSA in TBS for 20 minutes at 24 °C and washed with 
TBS prior to the addition of washed platelets.  Platelets were purified and adhesion assays 
conducted as previously described [17, 18].  Glanzmann thrombasthenic blood was kindly 
provided by Prof M.  Makris, Royal Hallamshire Hospital, Sheffield, UK.  GR144053 (4-[4-
[4-(aminoiminomethyl]-1-piperazinyl]-1-piperidineacetic acid hydrochloride trihydrate) was 
purchased from Calbiochem, Nottingham, UK.  The α2β1 integrin-binding peptide GFOGER 
(GPC[GPP]5-GFOGER-(GPP)5-GPC) and GPVI-binding peptide CRP-(XL) (GCO-[GPO]10-
GCOG; cross-linked where appropriate) and the inert GPP10 (GPC-[GPP]10-GPC) were 
generated as previously described [7] along with the anti–GPVI scFvs 10B12 and 1C3 and the 
non-GPVI-binding scFv 2D4 [19-23] which were a kind gift from Dr P.  Smethurst.  Human 
fibrinogen type I was purchased from Sigma, UK.  Anti–α2β1 antibody 6F1 was a kind gift 
from Prof B.  Coller (Mount Sinai Hospital, New York, USA).  RGDS (Arg-Gly-Asp-Ser) and 
cyclic RGD (H-Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys-OH) were purchased from 
Bachem, Weil am Rhein, Germany.  The fibrinogen-derived peptide, Lys-Gln-Ala-Gly-Asp-
Val (KQAGDV), was purchased from Innovagen, Sweden.  Inhibitory antibodies/compounds 
were used at 10 µM (6F1, 10B12, 1C3, 2D4, cRGD, GR144053, KQAGDV) or 100 µM 
(fibrinogen and RGDS).   
 
Flow cytometry 
In activation experiments, whole blood diluted 1:4 with Hepes buffered saline (HBS) was 
mixed for 10 min at 24 °C with an equal volume of 10 µg/ml mouse anti P-Selectin (Abcam, 
Cambs, UK) and the following agonists 2 mM proMMP-13(E204A) or MMP-13, 100 µg/ml 
CRP-XL, 100 µg/ml HORM equine collagen I fibers (Takeda, Linz, Austria), thrombin 
activating peptide (TRAP; 500 µM; Sigma, UK) calcium ionophore A23187 (100 µM; Sigma 
UK) or HBS (negative control) added.  Alexa 488 conjugated anti-mouse (30 µg/ml final 
concentration; Jackson Immuno Research, Ely, UK) was then added and after 10 min at 24 °C 
the volume was made up to 500 µl with isotonic solution. After 30 min fluorescence was 
measured using an Accuri C6 flow cytometer (BD Biosciences, Oxford, UK). In inhibition 
experiments, whole blood was pre-incubated with proMMP-13(E204A), GR144053 (20 µM) 
or 10B12 (10 µg/ml) for 20 minutes prior to the addition of CRP-XL. 
 
  
Solid phase adhesion assays.   
Recombinant human αIIbβ3 and GPVI monomer were obtained from R&D Systems 
(Abingdon, Oxford, UK).  Recombinant extracellular domain of GPVI (GPVIex, comprising 
D1D2 (amino acids 1–214; 42 kDa) fused with the Fc domain of human IgG (GPVI-Fc2, 150 
kDa) was prepared as previously described [24].   
HB 96-well plates (Nunc, Langenselbold, Germany) were coated with recombinant GPVI 
monomer or dimer (10 µg/ml in Phosphate-Buffered Saline (PBS)) for 1 h at 24 °C.  All further 
incubations were performed at room temperature for 1 h unless otherwise stated.  The wells 
were washed three times with adhesion buffer (1 mg/ml BSA in PBS containing 0.1 % (v/v) 
Tween-20) between each incubation step.  The wells were then blocked with 50 mg/ml BSA 
in TBS prior to the addition of MMP-13 at a concentration of 83 nM (unless otherwise stated) 
for 1 h at 24 °C in adhesion buffer.  Rabbit anti-MMP-13, raised against MMP-13 hinge region 
(Abcam, Cambridge, UK), and goat anti-rabbit HRP (Dako, Stockport, UK) were added at a 
dilution of 1:2000 in adhesion buffer prior to the addition of a TMB substrate system (Sigma, 
UK) and the plates read at 450 nm.   
 
Aggregometry 
Washed platelet aggregation was performed using a Chrono-Log turbidimetric aggregometer 
(Labmedics, Abingdon on Thames, UK).  250 µl aliquots of platelets, 2x108/ ml in calcium-
free Tyrodes buffer (CFT), were pre-incubated for 1 h with 80 nM MMP-13 or vehicle control 
prior to the addition of receptor agonists in a maximum volume of 5 µl.  Thrombin, calcium 
ionophore A23187 (San Diego, CA, USA), bovine collagen I fibers (Ethicon Corp, Somerville, 
NJ, USA), HORM and CRP–XL were prepared and employed to activate platelets as 
previously described [25, 26].  Aggregations were allowed to proceed for 5 min.   
 
Cleavage of platelet receptors and their substrates by MMP-13  
Recombinant human (rh)GPVI, purified αIIbβ3 (100 µg/ml, R&D Systems) and human 
fibrinogen type I (1 mg/ml) were incubated with MMP-13 or MMP-13(E204A) (8 µM final 
concentration) for 2 h at 37 °C.  An equal volume of Tris buffer was used as a negative control.  
Reducing sample buffer was then added to the mixture in preparation for electrophoresis and 
Western blotting. 
 
In vitro sheddase activity assays  
Dialysed MMP-13 at a final concentration of 130 nM was incubated with washed platelets for 
60 min at 37 °C.  Positive controls for shedding included thrombin (1 U/ml, Sigma, UK) 
combined with fibrous type I collagen (1 mg/ml), the calcium ionophore A23187 (1 µg/ml).  
The platelets were then pelleted at 1500 g for 1 min.  The supernatants were aspirated and 
centrifuged again to ensure platelet depletion.  This new supernatant was retained for analysis.  
Where indicated, platelet lysate was resuspended in reducing sample buffer. 
 
Electrophoresis and Western blotting 
Protein samples in reducing sample buffer were boiled for 5 min and applied to 4-12 % 
NuPage® Gels and separated by electrophoresis using the Xcell SureLock™ system 
(Invitrogen) under reducing conditions.  Proteins were then transferred on to nitrocellulose 
membrane (Millipore, Bedford, UK) at 40 V overnight at 4 °C using a Mini Protean II system 
(Bio-Rad, Hemel Hempstead, UK).  Following transfer, the PVDF was blocked (5 % non-fat 
dry powdered milk, 0.1 % Tween 20 in TBS) for 1 h and primary antibody was then added 
(1:1000 dilution) and incubated for 2 h at room temperature.  Anti-human GPVI was a kind 
gift from Dr P.  Smethurst, and anti-β3 was obtained from Abcam, Cambridge, UK.  Following 
washes with TBST, the membrane was incubated with HRP conjugated secondary antibody 
(1:10000 dilution/TBST) for 1 h at 24 °C.  The PVDF was developed using a chemiluminescent 
substrate (GE Healthcare, Amersham, Bucks, UK). 
 
Whole blood perfusion experiments 
Whole blood was pre-incubated with either carrier (TBS) or 80 nM MMP-13 for 1 h prior to 
perfusion over 10 µg/ml type I fibrous collagen as previously described [17, 25].  Where 
indicated, slides were coated with MMP-13(E204A) alone as a (negative) control. 
 
  
RESULTS  
Adhesion assays were performed in the presence of 2 mM EDTA or Mg2+ to ablate or support 
integrin-mediated adhesion.  Platelet adhesion to MMP-13 preparations was significantly 
reduced, but not abolished, by EDTA, suggesting both integrin-dependent and -independent 
contributions, whereas EDTA fully abolished binding to the collagen-binding integrin-specific 
peptide GFOGER (Figure 1A).   
Platelet pre-incubation with the αIIbβ3 antagonists, GR144053, cRGD and RGDS, and with 
anti-GPVI scFv 10B12 and 1C3, all caused a substantial and significant reduction (p < .01) in 
platelet adhesion to proMMP-13 (Figure 1A), with residual adhesion being observed in the 
presence of EDTA remaining above negative control levels (non-specific substrates).  This may 
indicate co-operative binding to αIIbβ3 and GPVI.  Interaction between MMP-13 and integrin 
α2β1 was less prominent, since blocking antibody 6F1 had just a small effect, and was not 
studied further.  Platelet pre-incubation with the fibrinogen-derived peptide, KQAGDV, had 
no effect on platelet adhesion, indicating that MMP-13 binds αIIbβ3 closer to the primary 
RGD-binding site.  Soluble fibrinogen also did not block platelet adhesion to MMP-13, in line 
with the need for platelet activation for soluble fibrinogen binding to αIIbβ3 to occur, whereas 
immobilised fibrinogen is already competent to bind.  The GPVI-specific scFv, 1C3, does not 
target the collagen-binding site at the apex of GPVI, unlike 10B12, and was unable to inhibit 
the adhesion of washed platelets to CRP (Figure 1B).  1C3 binding requires both GPVI Ig 
domains and is thought to reduce platelet activation by inhibiting receptor clustering; its epitope 
includes isoleucine 148 [21, 23], located in strand E on the opposite face of D2 to the crystal 
structure dimerisation interface located in strand G [24].  An indifferent control, the anti-HLA-
A2 scFv, 2D4, was inactive in these experiments.  In subsequent experiments, only low platelet 
binding was observed to isolated CAT and HPX domains of MMP-13 in comparison with the 
intact protein (Figure 1C), indicating that neither domain alone governs the interaction between 
the MMP and platelets, and supporting the possibility that two sites on MMP-13 co-operate to 
bind αIIbβ3 and GPVI.   
Competition assays in which washed platelets were pre-incubated with increasing amounts of 
the catalytically-dead MMP-13(E204A) provided further evidence that MMP-13 interacts with 
both GPVI and αIIbβ3; like GR144053 and 10B12, MMP-13 can compete αIIbβ3 off 
immobilised fibrinogen and GPVI off CRP (IC50 150 ng/ml and ~10 ng/ml respectively; 
Figures 2A(i-iv)).  Solid phase binding assays to coated isolated receptors revealed that MMP-
13 was able to bind weakly to GPVI monomer, but strongly to the GPVI dimer (Figure 2A(v)).  
Similar assays of adhesion to recombinant αIIbβ3 revealed some binding of its native ligand, 
fibrinogen, but little or no binding of MMP-13, regardless of whether Mg2+, Mn2+ or Ca2+ was 
present, nor could we detect binding of MMP-13 to purified αIIbβ3 (results not shown).  
Adhesion of αIIbβ3-null Glanzmann platelets to MMP-13, however, was markedly reduced 
(Figure 2B(i)).  Blockade of αIIbβ3 on healthy platelets resulted in the same adhesion level as 
seen for αIIbβ3-null platelets.  As expected, binding of Glanzmann platelets to fibrinogen was 
abolished (Figure 2B(ii)) and to CRP was unaffected (Figure 2B(iii)).  Our results indicate that, 
whilst MMP-13 appears able to bind to αIIbβ3 on the platelet surface, recombinant αIIbβ3 used 
here cannot reproduce this effect. 
Whilst it was able to cleave the recombinant αIIbβ3 β-chain and GPVI in solution, as well as 
fibrinogen α and β chains (Figure 3A), MMP-13 was unable to either cause or mediate shedding 
of either receptor in situ (Figure 3B).  
Pre-incubation of washed platelets for 1 h with 80 nM MMP-13(E204A) significantly reduced 
platelet aggregation to a series of agonists, and for the mid-range dose of each, analysed using 
2-way ANOVA, the inhibitory effect of MMP-13 was significant (p < .01).  Prominent amongst 
these stimuli were: CRP-XL, ionophore A23187, and bovine fibrillar collagen I, for which it 
was easier to establish mid-range doses than for thrombin and equine fibrillar collagen.  A 
summary of results is shown in Figure 4A and representative traces in Figure 4B.  MMP-13 
does not activate platelets measured by flow cytometry: no change in fluorescence using the 
anti-P-Selectin antibody was observed following the incubation of whole blood with pro-
MMP-13(E204A) or MMP-13, whereas clear expression was seen following treatment with 
CRP-XL, TRAP, HORM and ionophore A23187 (Figure 5A). In addition, MMP-13 does not 
promote the aggregation of washed platelets (Figure 4B(i)). Subsequent flow cytometry 
experiments revealed that unlike the anti-GVI scFv 10B12, neither proMMP-13(E204A) nor 
GR144053 (a potent αIIbβ3 antagonist) are able to alter secretion following platelet activation 
via CRP-XL (Figure 5B). This would suggest that in solution, the polymeric CRP-XL is a more 
potent ligand than MMP-13, and that the interaction of MMP-13 with αIIbβ3 predominates 
over that with GPVI. 
We investigated the influence of MMP-13 or MMP-13(E204A) on platelet adhesion and 
activation in flowing blood in vitro, using fibrillar collagen I coatings and a shear rate of 1000s-
1.  Pre–incubation of whole blood with MMP-13 resulted in significantly reduced platelet 
surface coverage (p < .05), mean thrombus height (p < .01), and ZV50 (p < .05), using one-way 
ANOVA and Holm multiple comparison test; Figure 6A(i-iii).  ZV50 is the height within a Z-
stack at which thrombus volume = 50% and describes the activation state of adhered platelets 
in flowing human blood [25].  Data obtained using pre-incubations with MMP-13(E204A) 
reached significance only for mean thrombus height (p < .05, Figure 6A(ii)).  MMP-
13(E204A)-coated slides were not able to support platelet adhesion under flow (Figure 6A(i-
iii)).  These results indicate that the interaction of MMP-13(E204A) with platelet GPVI and 
αIIbβ3 is sufficient to reduce platelet thrombus height.  Catalytically active MMP-13, whilst 
unable to cleave these receptors off the platelet surface, appears more able to inhibit platelet 
deposition.  MMP-13 co-coated with collagen type I did not significantly alter platelet 
aggregate formation under flow conditions (Figure 6B(i-iii)).  Interaction of active MMP-13 
with other blood components is not excluded by the present work, and further study is 
indicated. 
 
DISCUSSION 
We have previously shown that degradation by MMP-13 has the potential to modulate platelet 
adhesion to collagen [17]. MMPs are zymogens; proteolysis is required to expose their catalytic 
site.  Here we show that surprisingly, all forms of MMP-13, pro- and active wild type enzyme 
as well as their catalytically inactive mutant counterparts, were able to support a high level of 
platelet adhesion under static conditions. This adhesion was inhibited by the anti-GPVI scFvs 
10B12 and 1C3 suggesting that the relatively large MMP-13 occludes the sites of both 10B12 
and 1C3 binding on the receptor.  MMP-13 was also able to bind strongly to the GPVI dimer. 
Although GPVI dimerization increases upon platelet activation, dimeric GPVI is also present 
on resting platelets and is required for their initial interaction with exposed collagen [26]. 
Crystallography of the proMMP-13 structure in complex with pro-domain peptides revealed a 
dimeric form as an HPX-mediated dimer like some other metalloproteinases, although in this 
study [27], MMP-13 was not dimeric in solution.  Conceivably, interaction of MMP-13 with 
platelet surface GPVI dimer may provide a template for dimerization of the MMP.  Platelet 
adhesion to MMP-13 was also inhibited by the anti-αIIbβ3 compound GR144053, and binding 
of Glanzmanns αIIbβ3-null platelets to MMP-13 was significantly reduced. Following pre-
incubation of washed platelets with MMP-13, neither GPVI nor αIIbβ3 was shed from the 
platelet surface. It would appear, therefore, that whilst able to bind to platelet αIIbβ3 and GPVI, 
the orientation of MMP-13 on the platelet surface does not allow access of its CAT domain to 
the cleavage site, which, for other sheddases, resides close to the trans-membrane region and 
is regulated by membrane structure [28] or substrate phosphorylation [29]. Pre-incubation with 
MMP-13 did not result in platelet activation or aggregation. Here it is worth noting that MMP-
13 has been reported to cleave and thus activate PAR-1 on cardiac cells [30].  This has not been 
demonstrated on platelets, and may result in platelet activation concomitant with αIIbβ3 
inhibition, however in this case the catalytically inactive proMMP-13(E204A) is rendered 
unable to cleave the PAR-1 receptor. 
Coated as a substrate, MMP-13 is independently unable to support platelet adhesion in whole 
flowing blood, and its co-localisation with collagen does not result in an increase in platelet 
binding.  In solution however, MMP-13 is able to interact with platelet receptors GPVI and 
αIIbβ3 thereby modulating both platelet aggregation and thrombus formation under flow. 
Whilst MMP-13 is able to compete with immobilised CRP-XL for occupation of the GPVI 
receptor, our flow cytometry experiments reveal that the interaction of the MMP with platelets 
is insufficient to compete with the polymeric solution-phase CRP-XL and so alter platelet 
secretion. In this respect, it behaves much like the αIIbβ3 antagonist, GR144053, and it would 
appear therefore that the inhibitory effects of MMP-13 in solution are mediated predominantly 
through αIIbβ3. At concentrations comparable to those reached in stroke patient plasma and 
found to correlate with severity of infarction [31], MMP-13 can interact with both GPVI and 
αIIbβ3, and can compete with CRP and fibrinogen for occupation of these receptors.  MMP-
13 is unable to cleave GPVI and αIIbβ3 from the platelet surface however, and appears to exert 
its effects by direct physical blockade of receptor engagement.   
Until now, the role of MMP-13 in atherothrombosis has been considered to be restricted to 
collagen proteolysis and remodelling, rendering plaque more friable and prone to rupture [1].  
However, MMPs are now emerging as important mediators of platelet function [32, 33].  
MMPs -1 and -2 are released from activated platelets where they co-localise with integrins at 
the sites of platelet-platelet interaction [10, 34].  Active MMP-1 and -2 can stimulate platelet 
function, suggesting receptor engagement and proteolysis [34, 35].  MMPs in atherosclerotic 
lesions, released from the injured vessel wall itself or from platelets and monocytes, and that 
can also interact with platelets, are likely to interfere with the progression of plaque rupture, 
subsequent thrombosis and its associated pathologies including stroke, reperfusion injury and 
haemorrhagic transformation.  Indeed, these processes are associated with an upregulation of 
MMP activity [2, 31, 36].  In mice, MMP-13 is the key mediator of collagen degradation in 
atheroma and confers instability onto the vulnerability plaque cap [37-39].  Disruption of the 
blood brain barrier (BBB) by MMPs is associated with haemorrhagic transformation following 
ischemic stroke [36, 40, 41], whilst MMPs -9 and -13 are implicated in the early pathology of 
stroke progression, and plasma MMP-13 levels correlate with lesion volume [2, 31].  In 
addition, the platelet collagen receptor GPVI has been identified in models of models of 
reperfusion injury [42], is associated with increased risk of stroke development, and is also 
seen after ischemic stroke [43]. 
Here we demonstrate that MMP-13 can exert an anti-thrombotic effect; inhibiting platelet 
aggregation and thrombus formation in flowing whole blood.  It may be that this 
metalloproteinase has multiple roles in the pathology of ischaemic stroke; firstly by 
undermining the stability of the fibrous cap of atheroma and so promoting its rupture, then 
modulating the BBB to increase bleeding risk, and finally acting on platelets to impair the 
aggregatory interactions, by antagonising GPVI and αIIbβ3 which would normally protect 
against bleeding.  MMP-13 would appear therefore to modulate the architecture around sites 
of infarction to increase both risk of stroke and its haemorrhagic complications.  The effect of 
MMP-13 will depend upon its local level and the exposure of MMP-13-binding matrix 
components and warrants further investigation. 
  
FIGURE LEGENDS 
 
Figure 1.  Washed platelet adhesion assays.  (A) Platelets adherent to 10 µg/ml coated MMP-13 
variants in the presence of 2 mM Mg2+ (red bars) or 2 mM EDTA (orange bars) where stated.  Where 
appropriate, platelets were pre-incubated with anti-GPVI, αIIbβ3 or α2β1
 
antagonists.  BSA and GPP10 
were used as Mg2+-independent negative controls.  The platelet α2β1
 
binding-peptide GFOGER was 
included as an Mg2+ dependent positive control.  * p < .05; ** p < .01; † (one-way ANOVA and Holm 
multiple comparison test) relative to untreated platelets in either the presence of Mg2+ or EDTA, as 
appropriate.  (B) Inhibition of platelet adhesion to CRP by anti-GPVI scFvs as described above (C) 
Platelets adherent to MMP-13(E204A) and MMP-13 CAT and HPX domains.  CRP-XL was used as a 
positive control.  ** p < .01  (one-way ANOVA and Holm multiple comparison test) relative to adhesion 
to MMP-13(E204A).  Data represent mean A405 ± S.E. of three experiments.   
 
Figure 2.  Competition, GPVI and Glanzmann platelet binding assays.  (A) MMP-13(E204A) and 
either 10B12 or GR144053 were used to obtain IC50 values for the inhibition of washed platelet adhesion 
to 10 µg/ml coated fibrinogen (i, iii) or CRP (ii, iv) respectively.  (v) Adhesion of MMP-13(E204A) to 
recombinant human GPVI monomer and dimer.  Plates were coated with 10 µg/ml GPVI or BSA as a 
negative control.  MMP-13(E204A) at a concentration of 83 nM was allowed to adhere for 1 h at room 
temperature, then detected using an antibody directed at the MMP-13 linker region, as described in 
Experimental Procedures.  Data represent mean A450 ± S.E.  of three experiments.  (B) Platelets from a 
healthy donor (red bars) and from a Glanzmann thombasthenic individual (orange bars) were allowed 
to adhere to MMP-13, Fibrinogen and CRP-XL coated plates.  Where appropriate, platelets were pre-
incubated with anti-GPVI (1C3), or αIIbβ3 antagonists as described for Figure 1.  Data represent mean 
A405 ± S.E.  of duplicate readings for one experiment due to the rarity of the Glanzmann donor. 
 
Figure 3.  Platelet receptor cleavage and shedding assays.  (A) Degradation analysis of recombinant 
platelet receptors by active and MMP-13(E204A).  Recombinant human (rh)GPVI and purified αIIbβ3 
and fibrinogen type I were incubated with MMP-13 or MMP-13(E204A) for 2 h at 37 oC.  An equal 
volume of Tris buffer was used as a negative control.  Samples were subjected to electrophoresis under 
reducing conditions and Coomassie stained.  Images are representative of three experiments.  (B) 
Shedding analysis of platelet receptors.  Washed platelets were incubated with the calcium ionophore 
A23187, a thrombin and collagen type I mixture or MMP-13 for 1 h at 37 °C.  The platelets were then 
pelleted, the supernatant isolated and subjected to SDS-PAGE under reducing conditions and Western 
blotted.  Platelet GPVI and the integrin β3 chain were detected using the appropriate antibodies as 
described in materials and methods.  Recombinant human GPVI or αIIbβ3 were loaded onto the gels 
where appropriate as positive controls.  Images are representative of three experiments. 
  
Figure 4. Inhibition of platelet aggregation by MMP-13(E204A).  Different agonists were added to 
washed platelets following pre-incubation with 80 nM MMP-13(E204A).  The equivalent volume of 
0.01 M acetic acid was used as a negative control. Mean donor responses performed in duplicate and 
repeated three times with different donors are shown in (A), and representative individual traces in 
response to MMP-13 only, A23187, thrombin, cross-linked collagen related peptide (CRP-XL), 
HORM and type I collagen shown in (B).  
 
Figure 5. Activation of platelets in whole blood. Whole blood was mixed with anti P-Selectin and the 
agonists 2 mM proMMP-13(E204A)/MMP-13, 100 µg/ml CRP-XL, 100 µg/ml HORM equine 
collagen I fibers, thrombin activating peptide (TRAP; 500 µM) calcium ionophore A23187 (100 µM) 
or HBS (negative control) added.  Alexa 488 conjugated anti-mouse was then added and after 10 min 
at 24 °C the volume was made up to 500 µl with isotonic solution. After 30 min fluorescence was 
measured using an Accuri C6 flow cytometer (BD Biosciences, Oxford, UK). Data represent mean A450 
± S.E.  of three separate donors.  ** p < .005; (one-way ANOVA and Holm multiple comparison test). 
 
Figure 6. Platelet adhesion and thrombus deposition on fibrillar type I collagen. Untreated whole 
blood and blood pre-incubated with 80 nM MMP-13 or negative control where stated was drawn 
through a flow chamber for 5 min over (A) collagen type I fibers or (B) collagen type I fibers co-coated 
with MMP-13 using a syringe pump to generate a wall shear rate of 1000s-1, corresponding to arteriolar 
conditions.  Surface coverage (i) mean height (ii) and (iii) ZV50 are the mean taken from a minimum of 
three different donors as measured using confocal microscopy.  * p < .05; ** p < .01; (one-way ANOVA 
and Holm multiple comparison test) relative to MMP-untreated platelets. 
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